

Wrightington, Wigan and Leigh Teaching Hospitals

NHS Foundation Trust

Information Governance Department

Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk

Web: www.wwl.nhs.uk

Ref: FOI/2025/10651

Date Received: 4th April 2025

Response Due: 7th May 2025

Date: 9th April 2025

Dear Sir/Madam

With reference to your request for information received on 4th April 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do not hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

I would like to request data on the treatment of patients with hormone therapies for prostate cancer at your Trust for the period January 1, 2023- December 31, 2024. Specifically, I am seeking the following information:

Request for Information:

For each of the following hormone therapies used to treat prostate cancer, please provide the number of patients treated at your Trust between 01 January and 31 December (by years 2023 and 2024). For each therapy, broken down the data into the following categories:

- 1. Total Number of Patients Treated for ICD-10 C61 / M1-M1c (metastatic)**
- 2. Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M1-M1c (metastatic)**
- 3. Number of Patients for Whom Hormone Therapy Was Continued; ICD-10 C61 / M1-M1c (metastatic)**
- 4. Number of patients for whom docetaxel was initiated for ICD-10 C61 / M1-M1c (localised & metastatic)**

The hormone therapies of interest are:

- a. ADT alone**
- b. Abiraterone (Zytiga) in combination with any ADT**
- c. Abiraterone (Zytiga) – no ADT**
- d. Enzalutamide (Xtandi) in combination with any ADT**

- e. Enzalutamide (Xtandi) – no ADT
- f. Apalutamide (Erleada) in combination with any ADT
- g. Darolutamide (Nubeqa) in combination with any ADT
- h. Darolutamide (Nubeqa) in combination with any ADT with docetaxel
- i. Docetaxel in combination with any ADT

Total number of patients in each year, for each therapy for whom:

- Hormone therapy was initiated
- Hormone therapy was continued
- Docetaxel was initiated

I would appreciate it if you could provide the information in an electronic format, preferably in the attached spreadsheet format.

The Trust does not administer chemotherapy or immunotherapy treatment at WWL for prostate cancer as these patients are transferred to the Christie Hospital. Patients are administered Abiraterone, Enzalutamide and Darolutamide on site however these are patients of the Christies and are receiving care via a visiting Christie Consultant.

Therefore, please redirect your questions to the Christies Hospital FOI team at the-christie.foi@nhs.net.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Hazel Hendriksen
Divisional Director of Operations for Specialist Services

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111